Bevacizumab: Not as good with more adverse reactions?

Clinical and Experimental Ophthalmology

Volumn 39, Issue 6, 2011, Pages 588-590

  Beaumont, Paul ^a  

^a Retina and Vitreous Centre   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

BACTERIAL INFECTION; DIGESTIVE SYSTEM ULCER; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HUMAN; LETTER; MYCOSIS; RETINA MACULA AGE RELATED DEGENERATION; RISK ASSESSMENT; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM; VIRUS INFECTION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; HUMANS; MACULAR DEGENERATION; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79961186710     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2011.02606.x     Document Type: Letter

References (16)

1. The CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-908.
2. Rosenfeld, PJ. Bevacizumab versus ranibizumab - the verdict. N Engl J Med 2011; 364: 1966-7. DOI: 10.1056/NEJMoa10.1056.
3. The CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. Supplementary Appendix. Accessed 6 May 2011. Available from:
4. Beaumont PE, Kang H. Kwon ranibizumab and nonocular hemorrhage. Ophthalmology 2009; 116: 1593.
5. Gillies MC, Wong TY. Ranibizumab for neovascular age related macular degeneration. N Engl J Med 2007; 356: 748-9.
6. Genentech. Avastin labeling text (FDA approval date of May 2009). Available from:
7. Nalluri SR, Chu D, Keresztes R, ZhuX WS. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300: 2277-85.
8. Saif MW, Mehra R. Incidence and management of bevacizumab-related toxicities in colorectal cancer. Expert Opin Drug Saf 2006; 5: 553-66.
9. Allen JA, Adlakha A, Bergethon PR. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol 2006; 63: 1475-8.
10. Bevacizumab: new drug. Metastatic colorectal cancer: good in theory, not in practice. Prescrire Int 2006; 15: 94-7.
11. Bevacizumab: serious neurological disorders and nasal perforations. Prescrire Int 2007; 16: 112.
12. Zhong ZD, Zou P, Hu XS, You Y, Chen ZC, Huang SA. Effects of adenovirus mediated vascular endothelial growth factor gene transfer on reconstitution of hematopoiesis in post-bone marrow transplantation mice. Chin Med J (Engl) 2005; 118: 289-95.
13. Yasukawa K, Terai M, Shulman ST, Toyozaki T, Yajima S, Kohno Y, Rowley AH. Systemic production of vascular endothelial growth factor and fms-like tyrosine kinase-1 receptor in acute Kawasaki disease. Circulation 2002; 105: 766-9.
14. Proescholdt MA, Jacobson S, Tresser N, Oldfield EH, Merrill MJ. Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats. J Neuropathol Exp Neurol 2002; 61: 914-25.
15. Zhang J, Silva J, Yarovinsky T etal. VEGF blockade inhibits lymphocyte recruitment and ameliorates immune-mediated vascular remodelling. Circ Res 2010; 107: 408-17. Epub 10 Jun 2010.
16. Bressler NM, Chang TS, Suñer IJ etal. for the MARINA and ANCHOR Research Groups. Vision-related function after ranibizumab treatment by better- or worse-seeing eye clinical trial results from MARINA and ANCHOR. Ophthalmology 2010; 117: 747-56.